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A Case of Cerebrospinal Fluid
Viral Escape on a Dual
Antiretroviral Regimen: Worth
the Risk?
TO THE EDITOR—Among human immu-
nodeﬁciency virus (HIV)-infected pa-
tients on antiretroviral therapy (ART),
incomplete viral suppression in cerebro-
spinal ﬂuid (CSF) may occur even with
undetectable plasma viremia [1–4].
Treatment simpliﬁcation with “less-drug
regimens” may favor adherence and reduce
toxicity, but raises concerns on lower central
nervous system (CNS) drug penetration and
subsequent CNS viral escape [5, 6], as in the
case we report herein.
A 47-year-old HIV-infected woman,
receiving different ART regimens since
2002, in 2007 withdrew emtricitabine
due to lower-limb neuropathy, and main-
tained plasma viral control with daruna-
vir/ritonavir 600/100 mg twice daily and
tenofovir (in February 2013: HIV RNA
<40 copies/mL; CD4 lymphocyte count,
508 cells/µL). InMarch 2013, shewas hos-
pitalized after complaining of lower-limb
weakness and pain, headache, dizziness,
and dysarthria. Brain magnetic resonance
imaging (MRI) showed extensive signal
abnormalities (Figure 1A); lumbar punc-
ture revealed CSF total protein of 76
mg/dL with oligoclonal immunoglobulin
G bands, normal glycorrhachia, and cell
count. CSF cultures and examinations
for opportunistic infections (Cryptococcus
neoformans, Epstein-Barr virus, cytomega-
lovirus, human herpesvirus 8, JC virus)
were negative, and the CSF HIV RNA load
was 2715 copies/mL. Genotypic testing
showed the presence of multiple protease
inhibitor (PI)–associated mutations (V32I,
I54V, V82A, I84V, L10I, L33F, K20R,
M36I) conferring intermediate resistance
to darunavir, and nucleoside/nucleotide
reverse transcriptase inhibitor–associated
mutations (M41L, T215Y, V90I), con-
ferring intermediate resistance to teno-
fovir. Thus, antiretroviral treatment was
changed with darunavir/ritonavir 600/
100 mg twice daily plus raltegravir 400 mg
twice daily plus etravirine 200 mg twice
daily. Two months later, the patient repor-
ted signiﬁcant symptom improvements:
the CD4 count was 759 cells/µL; both
plasma and CSF HIV RNAwere undetect-
able. One year later, brain MRI showed
clear improvements in radiological signs
(Figure 1B).
To our knowledge for the ﬁrst time,
here we describe a case of CSF viral escape
in an HIV-infected patient on suppressive
ART with a dual regimen. Previous cases
of CSF viral escape (with or without neu-
rological symptoms) were reported in pa-
tients with incomplete plasma HIV RNA
suppression, or treated with suboptimal
ART [1, 2]. Compared to others, this case
clearly illustrates the improvements of
neurological symptoms and radiological
signs (Figure 1A and 1B) after switching
ART, guided by genotypic resistance test-
ing on CSF. Recently, a higher CNS pene-
tration effectiveness ranking score of ART
has been associated with lower levels of
CSFHIVRNA, as well as improvements in
neurological and cognitive functions [7, 8].
Meanwhile, new therapeutic schemes have
been proposed for patients on suppressive
therapy to reduce toxicity and costs, such
as switching to dual regimens or to boost-
ed PI monotherapy [5,9].These approach-
es may, however, be limited by lower CNS
drug penetration, potentially leading to
CSF viral escape (already described with
boosted PI monotherapy) [5, 6]. In this
report, the results of HIV genotyping in
CSF suggest a CNS virus compartmental-
ization, with subsequent selection of
Figure 1. Brain MRI images before (A) and 48 weeks after (B) combination antiretroviral therapy
switch. A, Axial brain magnetic resonance imaging (MRI) demonstrating extensive signal abnormali-
ties in the white matter of the cerebral hemispheres and in both the middle cerebellar peduncles. B,
Axial brain MRI showing absence of alterations in the cerebral peduncles and a reduction of the areas
of altered signal in the cerebral white matter with the persistence of small areas of lesion.
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resistant variants replicating intrathecally.
Notably, signiﬁcant clinical and radiologi-
cal improvements were obtained by ART
optimization and consequent viral sup-
pression in CSF.
Caution is needed with simpliﬁcation
strategies, especially when treating people
with a long ART history and previous
neurological events; CSF viral escape
should be ruled out in HIV-infected pa-
tients with suppressed plasma viremia
presenting with neurological symptoms.
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